BUSTED: Aegerion CEO caught doing some fast-talking on 'Fast Money'

Aegerion Pharmaceuticals CEO Marc Beer learned one thing very clear last week: FDA officials apparently watch CNBC, specifically, the network's financial stock trading program Fast Money.

Aegerion Pharmaceuticals CEO Marc Beer learned one thing very clear last week: FDA officials apparently watch CNBC, specifically, the network's financial stock trading program Fast Money.

And a lesson he learned the hard way was to be more careful when making statements about the uses of...

More from Archive

More from Scrip

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.